|
 |
Animal Models
| Presentation type |
|
Track |
Abstract category |
Text |
|
|
|
|
|
| Late breakers only |
|
|
|
Posters with this symbol have been selected by the Scientific Programme Committee for distinction based on merit.
Posters with this symbol have an e-Poster available.
|
CDA074
Abstract
|
Drug-resistance and BED assay testing in newly diagnosed HIV-1 individuals in Honduras to determine transmitted drug resistance in recent or established infections
W. Murillo1,2,3, I. L. de Rivera1, S. Morales4, T. Dobbs5, B.S. Parekh5, J. Albert2,3
1Universidad Nacional Autónoma de Honduras, UNAH, Dpto. de Microbiología, Tegucigalpa, Honduras, 2Swedish Institute for Infectious Disease Control (SMI), Department of Virology, Stockholm, Sweden, 3Karolinska Institute (KI), Microbiology Department, Stockholm, Sweden, 4Centers for Disease Control and Prevention (CDC), The Global AIDS Program for Central America (GAP), Ciudad Guatemala, Guatemala, 5Center for Disease Control and Prevention (CDC), Division of AIDS, STD, TB Laboratory Research and Division of HIV/AIDS Prevention, Atlanta, United States
|
|
CDA075
Abstract
|
Devlopment of a high-throughput HIV-1 drug-screening assay provides a reliable and affordable testing service for the generation of novel anti-retroviral compounds
D. Wang1, M. Luo1, X. Liu1, A. Penn-Nicholson1, J. Woratanadharm1, D. Einfeld1, J. Glock1, J. Dong1,2
1GenPhar, Inc., Mount Pleasant, United States, 2Medical University of South Carolina, Department of Microbiology and Immunology, Charleston, United States
|
|
CDA076
Abstract
|
HIV-1 drug resistance mutations and viremia levels among patients on combination antiretroviral therapy in Honduras
W. Murillo1, Y. Chunfu2, I. L. de Rivera1
1Universidad Nacional Autonoma de Honduras, UNAH, Microbiology Department, Tegucigalpa, Honduras, 2Center for Disease Control and Prevention (CDC), International Lab Branch - Global AIDS Program (GAP), Atlanta, United States
|
|
CDA077
Abstract
|
Development of dual-targeted antivirals against HIV and herpesviruses
C. Vanpouille1, A. Lisco1, M. Derudas2, J.-C. Grivel1, R.F. Schinazi3, C. Mcguigan2, J. Balzarini4, L. Margolis1
1NIH, Eunice Kennedy Shriver NICHD, Bethesda, United States, 2Cardiff University, Welsh School of Pharmacy, Cardiff, United Kingdom, 3Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, United States, 4Katholieke Universiteit Leuven, Rega Institute for Medical Research, Leuven, Belgium
|
|
Back to the Programme-at-a-Glance
|
|